Palatin Technologies, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1986-01-01

Employees: 34

Market Cap: $28.8M

Website: http://www.palatin.com

Clinical Trials

A Phase 2 Study Evaluating the Co-Administration of Bremelanotide With Tirzepatide for the Treatment of Obesity

Phase 2

Recruiting

Conditions: Obesity

Interventions: Drug: Bremelanotide
Drug: Tirzepatide

First Posted Date: 2024-08-22

Last Posted Date: 2024-08-22

Lead Sponsor: Palatin Technologies, Inc

Target Recruit Count: 60

Registration Number: NCT06565611

Locations: 🇺🇸
University Clinical Research-DeLand LLC, d/b/a Accel Research, DeLand, Florida, United States
🇺🇸
Lynn Health Science Institute, Oklahoma City, Oklahoma, United States
🇺🇸
Coastal Carolina Research Center, North Charleston, South Carolina, United States

and more 1 locations

A Phase IIb, Multicenter, Open-Label, Prospective Study of Bremelanotide in Diabetic Kidney Disease

Phase 2

Completed

Conditions: Kidney Disease

Interventions: Drug: Bremelanotide
Drug: RAAS inhibition therapy

First Posted Date: 2023-02-02

Last Posted Date: 2024-10-17

Lead Sponsor: Palatin Technologies, Inc

Target Recruit Count: 16

Registration Number: NCT05709444

Locations: 🇺🇸
Northeast Research Center, LLC, Bethlehem, Pennsylvania, United States
🇺🇸
Nephrotex Research Group, Dallas, Texas, United States
🇺🇸
California Institute of Renal Research, Chula Vista, California, United States

and more 6 locations

Phase 2a To Evaluate PL-8177 in Subjects With Active Ulcerative Colitis (UC)

Phase 2

Recruiting

Conditions: Ulcerative Colitis
Ulcerative Colitis Acute
Ulcerative
Ulcerative Colitis Flare

Interventions: Drug: PL8177
Drug: PL8177 Placebo

First Posted Date: 2022-07-20

Last Posted Date: 2024-01-10

Lead Sponsor: Palatin Technologies, Inc

Target Recruit Count: 28

Registration Number: NCT05466890

Locations: 🇺🇸
Kansas Gastroenterology, Wichita, Kansas, United States
🇺🇸
Gastroenterology Clinic of Acadiana, Lafayette, Louisiana, United States
🇺🇸
Delta Research Partners, Monroe, Louisiana, United States

and more 11 locations

A Phase 3, Multi-Center Study Evaluating PL9643 in Patients with Dry Eye

Phase 3

Completed

Conditions: Dry Eye
Dry Eye Syndromes

Interventions: Drug: PL9643 Ophthalmic Solution
Drug: Vehicle Ophthalmic Solution

First Posted Date: 2022-01-21

Last Posted Date: 2024-10-17

Lead Sponsor: Palatin Technologies, Inc

Target Recruit Count: 575

Registration Number: NCT05201170

Locations: 🇺🇸
Global Research Management, Glendale, California, United States
🇺🇸
Eye Research Foundation, Newport Beach, California, United States
🇺🇸
East West Eye Institute, Torrance, California, United States

and more 14 locations

Study to Evaluate Sex Differences in the Acute Effects of PL-3994 in Heart Failure Subjects

Phase 2

Conditions: Heart Failure With Preserved Ejection Fraction

Interventions: Drug: PL-3994 Aqueous Intravenous Solution Dose Ascention
Drug: PL-3994 Aqueous Intravenous Solution Single Dose

First Posted Date: 2020-03-23

Last Posted Date: 2021-12-14

Lead Sponsor: Palatin Technologies, Inc

Target Recruit Count: 55

Registration Number: NCT04318145

Locations: 🇺🇸
Northwestern University, Evanston, Illinois, United States

2. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder

Phase 3

Completed

Conditions: Hypoactive Sexual Desire Disorder

Interventions: Drug: Bremelanotide
Drug: Placebo

First Posted Date: 2015-01-15

Last Posted Date: 2021-01-28

Lead Sponsor: Palatin Technologies, Inc

Target Recruit Count: 714

Registration Number: NCT02338960

Locations: 🇺🇸
Palatin Clinical Site 263, Atlanta, Georgia, United States
🇺🇸
Palatin Clinical Site 204, Aventura, Florida, United States
🇺🇸
Palatin Clinical Site 285, Charleston, West Virginia, United States

and more 88 locations

1. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder

Phase 3

Completed

Conditions: Hypoactive Sexual Desire Disorder

Interventions: Drug: Bremelanotide
Other: Placebo

First Posted Date: 2015-01-07

Last Posted Date: 2021-04-09

Lead Sponsor: Palatin Technologies, Inc

Target Recruit Count: 723

Registration Number: NCT02333071

Locations: 🇺🇸
Palatin Clinical Site 142, Savannah, Georgia, United States
🇺🇸
Palatin Clinical Site 183, Bangor, Maine, United States
🇺🇸
Palatin Clinical Site 108, Melbourne, Florida, United States

and more 88 locations

Bremelanotide in Premenopausal Women With Female Sexual Arousal Disorder and/or Hypoactive Sexual Desire Disorder

Phase 2

Completed

Conditions: Hypoactive Sexual Desire Disorder
Female Sexual Arousal Disorder

Interventions: Drug: bremelanotide

First Posted Date: 2011-06-27

Last Posted Date: 2014-12-18

Lead Sponsor: Palatin Technologies, Inc

Target Recruit Count: 612

Registration Number: NCT01382719

Locations: 🇺🇸
Site 26, Huntsville, Alabama, United States
🇺🇸
Site 64, Mobile, Alabama, United States
🇺🇸
Site 52, National City, California, United States

and more 65 locations

Cross-Over Study of Subcutaneous Study Drug for the Treatment of Patients With Mild to Moderate Asthma

Phase 2

Withdrawn

Conditions: Asthma

Interventions: Drug: PL-3994

First Posted Date: 2011-02-25

Last Posted Date: 2014-12-16

Lead Sponsor: Palatin Technologies, Inc

Registration Number: NCT01304628

Safety Study of Subcutaneously Administered PL-3994 in Subjects With Controlled Hypertension

Phase 2

Completed

Conditions: Hypertension

Interventions: Drug: PL3994
Drug: Placebo

First Posted Date: 2008-05-30

Last Posted Date: 2013-07-19

Lead Sponsor: Palatin Technologies, Inc

Target Recruit Count: 21

Registration Number: NCT00686803

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy